Astrazeneca PLC (AZN) Social Stream
Featured Post From StockTwits About AZN
$AZNsbiswas, published November 23, 2020
AstraZeneca’s (NASDAQ:AZN) Imfinzi (durvalumab) has been approved in the U.S. for an additional dosing option, a 1,500mg fixed dose every four weeks, for Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy and previously treated bladder cancer.
View the full list of news/momentum plays on watch at : bit.ly/32GfaRt
[No bias / position]
[Find me at https://stocktwits.com/sbiswas | https://twitter.com/soumyajyoti_b]"